Last reviewed · How we verify
sorafenib, cisplatin, fluorouracil
At a glance
| Generic name | sorafenib, cisplatin, fluorouracil |
|---|---|
| Also known as | sorafenib with hepatic arterial infusion of low dose FP |
| Sponsor | Kindai University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anemia
- Fatigue
- Generalized muscle weakness
- Infections and infestations - Other, Bacteremia
- Neutrophil count decreased
- Platelet count decreased
- White blood cell decreased
- Febrile Neutropenia
- Dysgeusia
- Gastrointestinal disorders - Other, Hernia
- Hyponatremia
- Thromboembolic event
Key clinical trials
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery (PHASE3)
- Paediatric Hepatic International Tumour Trial (PHASE3)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP (PHASE1, PHASE2)
- Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE (PHASE2)
- Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (PHASE2)
- Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sorafenib, cisplatin, fluorouracil CI brief — competitive landscape report
- sorafenib, cisplatin, fluorouracil updates RSS · CI watch RSS
- Kindai University portfolio CI